This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Big Biotech Stocks Worth Considering Post Q3 Earnings
by Zacks Equity Research
We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Will Incyte (INCY) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Incyte (INCY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The Zacks Analyst Blog Highlights: Sony, Allstate and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sony, Allstate and Incyte
Earnings Season Clean Up: Global Week Ahead
by John Blank
71% of S&P 500 members have reported Q3 results. At Zacks, 'total earnings means 'aggregate net income' for those 357 S&P 500 members -- not mean, median or market-cap weighted EPS.
Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.
Incyte (INCY) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 26.15% and 2.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.
Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q3 Earnings?
by Zacks Equity Research
Rising competition in international markets for Humira might have hurt AbbVie's (ABBV) top line in the third quarter. However, strong growth of Imbruvica is expected to have offset the loss.
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings?
by Zacks Equity Research
During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.
Lannett (LCI) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet's (LCI) fiscal first-quarter 2020 results are likely to reflect strong performance of its anti-psychosis and cardiovascular drugs.
BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.
Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Will Top-Line Decline Hurt Corning's (GLW) Q3 Earnings?
by Zacks Equity Research
Softness in Display Technologies and Optical Communications business segments is likely to have hurt Corning's (GLW) third-quarter 2019 financial performance.
5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.
Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.
AstraZeneca (AZN) Q3 Earnings Top, Upgrades '19 Sales View
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.
Incyte Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Incyte has been struggling lately, but the selling pressure may be coming to an end soon.
Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance
by Zacks Equity Research
Alexion (ALXN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales growth in the third quarter.